HUMAN GENE THERAPY

Scope & Guideline

Leading the Charge in Genetic Advancements

Introduction

Explore the comprehensive scope of HUMAN GENE THERAPY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore HUMAN GENE THERAPY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1043-0342
PublisherMARY ANN LIEBERT, INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1990 to 2024
AbbreviationHUM GENE THER / Hum. Gene Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801

Aims and Scopes

The journal 'Human Gene Therapy' focuses on the latest advancements in gene therapy, emphasizing innovative approaches to treat genetic disorders and related diseases. Its scope encompasses a wide variety of topics, including gene editing technologies, vector development, and clinical applications of gene therapy.
  1. Gene Therapy Development and Application:
    The journal highlights research dedicated to developing new gene therapy techniques and their applications in clinical settings. This includes studies on various diseases, particularly genetic disorders.
  2. Gene Editing Technologies:
    There is a strong emphasis on novel gene editing technologies, including CRISPR/Cas9 and related systems, which are explored for their potential to correct genetic defects.
  3. Viral Vector Innovations:
    Research on viral vectors, especially adeno-associated viruses (AAV), plays a crucial role in the journal. Studies focus on enhancing vector efficiency, specificity, and safety for delivering therapeutic genes.
  4. Clinical Trials and Translational Research:
    The journal publishes findings from clinical trials, contributing to the understanding of gene therapy's efficacy and safety in human populations. This includes phase I/II studies and long-term follow-up assessments.
  5. Mechanisms of Gene Therapy:
    Investigations into the underlying mechanisms of gene therapy, including immune responses, vector biodistribution, and gene expression regulation, are central to the journal's contributions.
The landscape of gene therapy research is rapidly evolving, with several emerging themes gaining traction. These trends highlight the journal's adaptability and responsiveness to the latest scientific advancements and societal needs.
  1. Advancements in CRISPR Technology:
    Recent publications show a significant increase in research related to CRISPR technology, including novel applications, improved precision, and safety measures in gene editing.
  2. Combination Therapies:
    There is a growing trend towards exploring combination therapies that integrate gene therapy with other treatment modalities, such as immunotherapy, to enhance efficacy against complex diseases.
  3. Personalized Gene Therapies:
    Research focusing on personalized medicine approaches, where therapies are tailored to individual genetic profiles, is on the rise, reflecting a broader trend in precision medicine.
  4. Gene Therapy for Rare Diseases:
    An increasing number of studies are dedicated to developing gene therapies for rare diseases, driven by the need for effective treatments for conditions that have limited options.
  5. Regulatory and Ethical Considerations:
    Emerging discussions around the regulatory landscape, ethical considerations, and the societal implications of gene therapy are becoming more prevalent in the journal, indicating a maturation of the field.

Declining or Waning

While 'Human Gene Therapy' continues to thrive in many areas, certain themes appear to be declining in prominence over recent years. These waning scopes reflect shifts in research focus or advancements in technology that have rendered previous topics less critical.
  1. Traditional Gene Therapy Approaches:
    There has been a noticeable decline in studies focused solely on traditional gene therapy methods, as more advanced techniques like CRISPR and other gene editing technologies gain traction.
  2. Basic Research on Gene Delivery Mechanisms:
    Basic studies exploring the mechanisms of gene delivery have decreased, likely due to the shift towards more applied research that directly informs clinical practices and safety assessments.
  3. Single-Gene Disorders Focus:
    Research specifically targeting single-gene disorders may be waning as the field broadens to encompass more complex genetic conditions and polygenic disorders, which require multifaceted therapeutic approaches.

Similar Journals

GENE

Illuminating the Path of Genetic Advancements
Publisher: ELSEVIERISSN: 0378-1119Frequency: 48 issues/year

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

CURRENT OPINION IN GENETICS & DEVELOPMENT

Pioneering advancements in developmental processes.
Publisher: CURRENT BIOLOGY LTDISSN: 0959-437XFrequency: 6 issues/year

CURRENT OPINION IN GENETICS & DEVELOPMENT is a prestigious journal published by CURRENT BIOLOGY LTD that offers an insightful platform for the latest developments and emerging trends in the fields of genetics and developmental biology. Established in 1991 and set to continue until at least 2024, this journal achieves notable recognition in the academic community with a Q1 classification in both its major categories as of 2023. With a Scopus rank placing it within the top quartile for both genetics and developmental biology, it serves as an essential resource for researchers, professionals, and students seeking to enhance their understanding of genetic mechanisms and developmental processes. While currently not an open-access journal, readers can explore the collection of high-quality articles that contribute to shaping contemporary scientific discourse and fostering innovation within these dynamic fields. For those dedicated to advancing their research and knowledge, CURRENT OPINION IN GENETICS & DEVELOPMENT stands as a vital and influential academic publication.

Molecular Therapy Methods & Clinical Development

Transforming science into impactful therapies.
Publisher: CELL PRESSISSN: Frequency: 1 issue/year

Molecular Therapy Methods & Clinical Development, published by CELL PRESS, is a premier Open Access journal dedicated to advancing the field of gene and cell therapy through innovative methodologies and clinical developments. Since its inception in 2014, the journal has garnered significant attention within the research community, achieving impressive Q1 quartile rankings in Genetics, Molecular Biology, and Molecular Medicine as of 2023. With a commendable Scopus ranking that positions it within the top echelons of its categories, this journal serves as an essential platform for researchers, professionals, and students alike, providing access to cutting-edge research that drives the future of therapeutic approaches. With its commitment to Open Access, readers worldwide can easily access high-quality and impactful content that fosters collaboration and knowledge-sharing in this rapidly evolving domain. The journal’s scope encompasses crucial advancements in therapeutic methodologies, ensuring that it remains at the forefront of scientific discourse and innovation.

CURRENT GENE THERAPY

Bridging Research and Clinical Practice.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1566-5232Frequency: 6 issues/year

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

Molecular Genetics & Genomic Medicine

Empowering the future of genomic medicine.
Publisher: WILEYISSN: 2324-9269Frequency: 12 issues/year

Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

JOURNAL OF GENE MEDICINE

Empowering the Next Generation of Molecular Medicine
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Neurotherapeutics

Elevating the Standard of Care through Cutting-Edge Research.
Publisher: SPRINGERISSN: 1933-7213Frequency: 4 issues/year

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

Molecular Therapy Nucleic Acids

Transforming research into breakthroughs in gene therapy.
Publisher: CELL PRESSISSN: 2162-2531Frequency: 4 issues/year

Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.

TRENDS IN GENETICS

Advancing the Frontiers of Genetic Research
Publisher: CELL PRESSISSN: 0168-9525Frequency: 12 issues/year

TRENDS IN GENETICS, published by CELL PRESS, is a leading journal in the field of genetics, recognized for its significant impact on research and advancements in the discipline. With an impressive Scopus ranking of #10 out of 347 in the category of Genetics and a 97th percentile ranking, this journal stands as a premier platform for publishing innovative, high-quality articles that shape the future of genetic research. Since its inception in 1985, TRENDS IN GENETICS has been at the forefront of the genetic sciences, continuously disseminating crucial findings while maintaining a strong commitment to scientific rigor and integrity. Although it does not currently offer open access options, its rigorous peer-review process ensures that only the most relevant and groundbreaking studies make it to publication. Scholars and practitioners in genetics will find this journal to be an invaluable resource for keeping abreast of the latest developments, trends, and methodologies that drive the field forward.

Molecular and Cellular Pediatrics

Bridging gaps in child health with pioneering research.
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular and Cellular Pediatrics is a leading journal published by SPRINGERNATURE, dedicated to advancing knowledge in the fields of pediatrics, perinatology, and child health through innovative molecular and cellular research. Since its transition to Open Access in 2014, the journal has facilitated widespread dissemination of critical findings, making it accessible to a global audience of researchers, healthcare professionals, and students. The journal's scope encompasses a range of topics that explore the intersection of molecular biology and pediatric medicine, aiming to bridge gaps in our understanding of child health and development. With Scopus rankings placing it at the 48th percentile in pediatrics and a significant focus on cutting-edge research, Molecular and Cellular Pediatrics plays an essential role in shaping future research and clinical practices in the field. Its commitment to academic rigor and accessibility makes it a vital resource for those dedicated to improving pediatric health outcomes.